Glutamine requirements in the generation of lymphokine-activated killer cells.

[1]  L. Filgueira,et al.  Exogenous glutamine requirement is confined to late events of T cell activation , 1993, Journal of cellular biochemistry.

[2]  A. Sodhi,et al.  Role of human blood monocytes in up-regulation of lymphokine (interleukin-2)-activated killer cell activity with cisplatin and FK-565. , 1992, Natural immunity.

[3]  S. Rosenberg,et al.  Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Lanier,et al.  The developmental relationship between NK cells and T cells. , 1992, Immunology today.

[5]  Whiteside Tl.  Cancer therapy with tumor-infiltrating lymphocytes: evaluation of potential and limitations. , 1991 .

[6]  P. Guillou.  Immunotherapy for cancer , 1991, The British journal of surgery.

[7]  E. Newsholme,et al.  The effect of time of addition of glutamine or nucleosides on proliferation of rat cervical lymph-node T-lymphocytes after stimulation by concanavalin A. , 1991, The Biochemical journal.

[8]  B. Knowles,et al.  Frequency of SV40‐specific cytotoxic T‐lymphocyte precursors in two SV40 T‐antigen transgenic mouse lines , 1991, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[9]  J. M. Lacey,et al.  Is glutamine a conditionally essential amino acid? , 2009, Nutrition reviews.

[10]  P. Calder,et al.  Does glutamine contribute to immunosuppression after major burns? , 1990, The Lancet.

[11]  D. Parkinson,et al.  Interleukin-2, killer cells and cancer therapy: an overview. , 1990, Natural immunity and cell growth regulation.

[12]  P. Luppa,et al.  Metabolism of glutamine in lymphocytes. , 1989, Metabolism: clinical and experimental.

[13]  E. Newsholme,et al.  The effect of glutamine concentration on the activity of carbamoyl-phosphate synthase II and on the incorporation of [3H]thymidine into DNA in rat mesenteric lymphocytes stimulated by phytohaemagglutinin. , 1989, The Biochemical journal.

[14]  S. Sone,et al.  Up‐regulation by granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) of induction of lymphokine (IL‐2)‐activated killer (LAK) cells by human blood monocytes , 1989, International journal of cancer.

[15]  O. Silvennoinen,et al.  Accessory cells, dendritic cells, or monocytes, are required for the lymphokine-activated killer cell induction from resting T cell but not from natural killer cell precursors. , 1988, Journal of immunology.

[16]  T. Abo,et al.  Prerequisite for the induction of lymphokine-activated killer cells from T lymphocytes. , 1988, Journal of immunology.

[17]  J. Gutterman,et al.  Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity. , 1988, Cancer research.

[18]  M. Ardawi.  Glutamine and glucose metabolism in human peripheral lymphocytes. , 1988, Metabolism: clinical and experimental.

[19]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[20]  W. Chan,et al.  The p75 peptide is the receptor for interleukin 2 expressed on large granular lymphocytes and is responsible for the interleukin 2 activation of these cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  C. Balch,et al.  Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. , 1987, Journal of immunology.

[22]  E. Lotzová,et al.  Reassessment of LAK phenomenology: a review. , 1987, Natural immunity and cell growth regulation.

[23]  N. Damle,et al.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors. , 1986, Journal of immunology.

[24]  J. Ortaldo,et al.  Lymphokine-activated killer cells. Analysis of progenitors and effectors , 1986, The Journal of experimental medicine.

[25]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[26]  L. Lanier,et al.  The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. , 1986, Journal of immunology.

[27]  M. Brunda,et al.  Interaction of recombinant interferons with recombinant interleukin‐2: Differential effects on natural killer cell activity and interleukin‐2‐activated killer cells , 1986, International journal of cancer.

[28]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[29]  B. Crabtree,et al.  Glutamine metabolism in lymphocytes: its biochemical, physiological and clinical importance. , 1985, Quarterly journal of experimental physiology.

[30]  J. Crawford,et al.  The essential role of L‐glutamine in lymphocyte differentiation in vitro , 1985, Journal of cellular physiology.

[31]  J. Roth,et al.  Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells , 1983, The Journal of experimental medicine.

[32]  E. Newsholme,et al.  Glutamine metabolism in lymphocytes of the rat. , 1983, The Biochemical journal.

[33]  S. Rosenberg,et al.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes , 1982, The Journal of experimental medicine.

[34]  P. Hersey,et al.  Induction of cytotoxic activity in human lymphocytes against autologous and allogeneic melanoma cells in vitro by culture with interleukin 2 , 1981, International journal of cancer.

[35]  S. Rosenberg,et al.  Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. , 1981, Cancer research.

[36]  C. Taswell,et al.  Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. , 1981, Journal of immunology.

[37]  I. Lefkovits.  Limiting Dilution Analysis , 1979 .

[38]  H. Eagle,et al.  Amino acid metabolism in mammalian cell cultures. , 1959, Science.

[39]  A. Meister.  Metabolism of glutamine. , 1956, Physiological reviews.